Tyr648
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr648  -  RoXaN (human)

Site Information
KVWLLQQySGMtHED   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450623
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 )
Disease tissue studied:
esophageal cancer ( 3 ) , esophageal carcinoma ( 3 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 ) , lymphoma ( 4 , 5 , 6 , 7 ) , anaplastic large cell lymphoma ( 4 , 5 , 6 , 7 )
Relevant cell line - cell type - tissue:

References 

1

Ren H (2011) CST Curation Set: 11784; Year: 2011; Biosample/Treatment: cell line, RP101/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

2

Wu F, et al. (2010) Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics 9, 1616-32
20393185   Curated Info

3

Tucker M (2010) CST Curation Set: 9225; Year: 2010; Biosample/Treatment: cell line, Kyse140/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

4

Goss V (2006) CST Curation Set: 1149; Year: 2006; Biosample1/Treatment/Isotope: cell line, TS/none/L, Biosample2/Treatment/Isotope: cell line, TS/none/H; Disease: anaplastic large cell lymphoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Boccalatte F (2005) CST Curation Set: 614; Year: 2005; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Rush J, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94-101
15592455   Curated Info

7

Moritz A (2003) CST Curation Set: 179; Year: 2003; Biosample/Treatment: cell line, Karpas-299/-; Disease: T cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info